Status: Recruiting
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Participants needed: 200
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Sound Pharmaceuticals, IncorporatedUpdated: Jun 2, 2026Locations: 9
Eligibility criteria
Adult males/females, 18-75 years of age at the time of enrollment. [+6]
Current, or within 60 days prior to study enrollment, use of IV or intratympanic... [+10]